PAX-101 is under clinical development by Paxmedica and currently in Phase III for African Trypanosomiasis. According to GlobalData, Phase III drugs for African Trypanosomiasis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how PAX-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Suramin (PAX-101) is under development for the treatment of human African trypanosomiasis (HAT), pervasive developmental disorder (PDD, autism spectrum disorder (ASD)) and fragile X syndrome tremor-ataxia (FXTAS), long COVID-19 syndrome (LCS) and myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). It is administered through intravenous route. The drug candidate acts by targeting P2X- and P2y purinergic receptors.
Paxmedica is an early clinical stage biopharmaceutical company. The Company is focused on the development of anti-purinergic therapies (APT) for the treatment of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Fragile X syndrome tremor-ataxia (FXTAS). Its pipeline includes PAX-101 and PAX-102. It is focused on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD, FXTAS and Human African Trypanosomiasis (HAT). Its lead neurodevelopmental indication for PAX-101 is ASD. PAX-102, an intranasal formulation of suramin, is also being developed for neurodevelopmental indications.It is headquartered in Woodcliff Lake, New Jersey, United States.
For a complete picture of PAX-101’s drug-specific PTSR and LoA scores, buy the report here.